Clinical

Dataset Information

0

Irinotecan and retetrasse combined with radiotherapy with or without bevacizumab in patients with recurrent colorectal cancer: a multicenter, prospective, randomized controlled clinical trial


ABSTRACT: Interventions: control group:Irinotecan was given intravenously at week 1, week 3 and week 5, 180 mg / m2; Retetrasse was given intravenous drip of 2 mg / m2 for 1 day at 1, 3 and 5 weeks; Concurrent radiotherapy: IMRT external radiotherapy.;Experimental group:Irinotecan was given intravenously at week 1, week 3 and week 5, 180 mg / m2; Retetrasse was given intravenous drip of 2 mg / m2 for 1 day at 1, 3 and 5 weeks; Bevacizumab was given intravenously for 1 day at week 1, 3 and 5; Concurrent radiotherapy: IMRT external radiotherapy. Primary outcome(s): Objective response rate Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 2699734 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-12-08 | E-MTAB-6515 | biostudies-arrayexpress
2023-12-08 | E-MTAB-6514 | biostudies-arrayexpress
2013-01-01 | GSE41998 | GEO
2020-11-15 | GSE140494 | GEO
2023-11-21 | PXD040451 | Pride
2013-01-01 | E-GEOD-41998 | biostudies-arrayexpress
| EGAS00001006736 | EGA
2024-07-29 | GSE248014 | GEO
| 2495080 | ecrin-mdr-crc
| 2456506 | ecrin-mdr-crc